EURETINA 2023: Safety and efficacy through week 48 in the Phase 2a STARLIGHT clinical trial
We spoke with Michael Singer, MD who provided an overview of his presentation, "MCO-010 Optogenetic Therapy to Treat Stargardt Disease: Safety and Efficacy through Week 48 in the Phase 2a STARLIGHT Clinical Trial"
The 23rd annual EURETINA Congress is underway in Amsterdam, the Netherlands. We spoke with Michael Singer, MD who provided an overview of his presentation, "MCO-010 Optogenetic Therapy to Treat Stargardt Disease: Safety and Efficacy through Week 48 in the Phase 2a STARLIGHT Clinical Trial."
Here's what he had to say about the meeting and his research.
Audio Transcript
Editor's note - This transcript has been edited for clarity.
Recent Videos
Related Content
